AHAngela Huebner

Angela Huebner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Angela Huebner has a total of 180 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MAScINSIGHT: A Real-World Data Study to Deepen Knowledge and Management of McCune-Albright Syndrome – Study Protocol for an Observational Study within OHDSI

    by Michele Zoch, Clemens Hentrich, Käty E. O. Mothes, Jens Weidner, Katja Hoffmann, Martin Sedlmayr, Angela Hübner, Christian Reich, Ines Reinecke, Georg Schwabe, et al.

    Introduction: McCune-Albright syndrome (MAS) is a rare congenital disorder affecting endocrine, skeletal and dermatological systems. MAS is often coded as fibrous dysplasia (FD) in routine health data, which includes other conditions and does not allow precise identification. This coding gap complicates reliable epidemiological estimates and clinical characterization. The study MAScINSIGHT aims to address this by investigating MAS features within FD-coded cohorts. Methods and analysis: MAScINSIGHT is a retrospective observational study using a federated network of data in the OMOP Common Data Model. Routine data from multiple sites will be analyzed within a federated setting to assess endocrine abnormalities and treatment patterns in patients with FD or MAS. Ethics and dissemination: Analyses will be performed locally at the data partner, with only aggregate statistics made available and centrally analyzed. The study protocol was approved by the ethics committee (reference number: 2026-18760-retrospektiv). Findings will be disseminated through open-access publications and patient-oriented reports. Strengths and limitations of this study: The study uses a federated approach based on the Observational Health Data Sciences and Informatics (OHDSI) framework and the OMOP Common Data Model, enabling standardized and reproducible analyses across institutions and countries while preserving data privacy. The multinational approach enables the analysis of larger and more diverse patient populations than typically available at individual institutions, addressing a major challenge in rare disease research. The integration of rare disease-specific terminologies, particularly ORPHAcodes, into the OHDSI vocabulary system supports more precise cohort identification and characterization, providing a transferable methodological approach for rare disease research. The retrospective design relies on routinely collected healthcare data, which may be affected by incomplete documentation, inconsistent coding practices and differences in data availability and quality across participating sites. Due to the rarity of McCune-Albright syndrome, sample sizes may remain limited despite the multinational approach, potentially restricting statistical power and subgroup analyses.

  • Open Access

    Health-Related Quality of Life in Children with X-Linked Hypophosphatemia Treated with Burosumab: Real-World Data from a German-Swiss Study

    by Ineke Böckmann, Martin Klein, Helena Mutze, Mirko Rehberg, Giuseppina Spartà, Katrina Evers, Karl Peter Schlingmann, Markus J. Kemper, Annette Richter-Unruh, Dorothee Schmidt, et al.

    Burosumab is effective in improving rickets in children with X-linked hypophosphatemia (XLH). Predictors of health-related quality of life (HRQoL) in pediatric XLH patients treated with burosumab are unknown. In this cross-sectional analysis of a prospective binational observational study, we investigated HRQoL in 64 pediatric XLH patients (36 female) on burosumab treatment, using the KIDSCREEN-52 questionnaire and qualitative interviews. Associations between HRQoL and clinical findings were analysed using multiple regression and receiver operating characteristics (ROC) curve analyses. Median age at investigation and duration of burosumab treatment were 13.1 (IQR 10.4; 14.8) and 2.8 (IQR 1.4; 3.8) years, respectively; 54.7% of patients received secondary burosumab treatment following prior active vitamin D and phosphate. Overall, HRQoL scores were comparable to national reference values. Caregivers rated Physical Well-Being, Moods & Emotions, and Bullying lower than the patients themselves. Burosumab dose was significantly associated with Physical Well-Being, Psychological Well-Being, and Self-Perception in self-report, and with total T-values and Physical Well-Being in proxy questionnaires. The duration of prior treatment with active vitamin D and phosphate was significantly associated with the dimension of Autonomy in self-report and proxy reports. A burosumab dosage above 0.6 mg/kg was associated with a good Physical Well-Being (above the mean of the general population) with a sensitivity and specificity of 75% and 70% in self-report, and 67% and 70% in proxy questionnaires, respectively. In this real-world study, HRQoL in burosumab-treated children with XLH was comparable to that of the general population and associated with burosumab dosage.


  • Open Access

    Diagnostic work-up in paediatric adrenocortical tumours: an international consensus.

    by Sonir R Antonini, Verena Wiegering, Mariana P Halah, Luís Eduardo Cruvinel Pinto, Navoda Attapatu, Katja Dumic Kubat, Jorge Elias, Nursah Eker, Martin Fassnacht, Maria C B V Fragoso, et al.

    Paediatric adrenocortical tumours (pACTs) are rare but potentially life-threatening neoplasms, most of which are hormonally active and frequently present with androgen excess. Although a comprehensive evaluation is recommended, no consensus exists on the optimal diagnostic work-up. The goal of this document is to provide evidence-based recommendations to standardize the diagnostic evaluation of children with suspected pACTs. We applied a modified three-step Delphi process with an international panel of pACT experts to develop consensus on the initial diagnostic work-up. Following a literature review, the steering committee formulated statements, which were distributed electronically to 28 experts from Europe, the Americas, and Asia. Agreement was rated on a six-point Likert scale; ≥70% agreement was defined as consensus. Between rounds, results and feedback were reviewed within the ENS@T-KIDS group. In round one, 33 statements achieved consensus; 12 were revised and re-voted in round 2, with 7 reaching consensus. Five statements were further modified and one reached consensus in round three. Response rates were 86% (n = 24) in round 1, 82% (n = 23) in round 2, and 86% (n = 24) in round 3. Forty-one statements received consensus covering 4 domains: (I) General Aspects and Clinical Assessment (17), (II) Endocrine Work-up (15), (III) Imaging (4), and (IV) Genetics (6). The diagnostic evaluation of pACTs varies widely between centres and countries, influenced by resources and local expertise. This work delivers the first expert-derived, international consensus statements outlining a practical and standardized diagnostic pathway to support timely and consistent evaluation of children with suspected pACTs.

  • Open Access

    Health-related quality of life of children with X-linked hypophosphatemia in Germany

    by Martin Klein, Michael Obermaier, Helena Mutze, Sophia Maria Wilden, Mirko Rehberg, Karl Peter Schlingmann, Dorothee Schmidt, Oliver Metzing, Angela Hübner, Anette Richter-Unruh, et al.

    Background: X-linked hypophosphatemia (XLH) is a rare inherited phosphate-wasting disorder associated with bone and dental complications. Health-related quality of life (HRQoL) is reduced in XLH patients on conventional treatment with phosphate supplements and active vitamin D, while information on patients treated with burosumab is rare. Methods: HRQoL was assessed in 63 pediatric XLH patients participating in a prospective, observational study and patient registry in Germany using the KIDSCREEN-52 survey instrument and standardized qualitative interviews. Results: The median age of the XLH patients was 13.2 years (interquartile range 10.6 – 14.6). At the time of the survey, 55 (87%) patients received burosumab and 8 (13%) conventional treatment. Forty-six patients (84%) currently being treated with burosumab previously received conventional treatment. Overall, HRQoL was average compared to German reference values (mean ± SD: self-report, 53.36 ± 6.47; caregivers’ proxy, 51.33 ± 7.15) and even slightly above average in some dimensions, including physical, mental, and social well-being. In general, XLH patients rated their own HRQoL higher than their caregivers. In qualitative interviews, patients and caregivers reported that, compared with conventional therapy, treatment with burosumab reduced stress, bone pain, and fatigue, improved physical health, and increased social acceptance by peers and the school environment. Conclusions: In this real-world study in pediatric XLH patients, HRQoL was average or even slightly above that of the general population, likely due to the fact that the vast majority of patients had their treatment modality switched from conventional treatment to burosumab resulting in improved physical health and well-being. Graphical


  • Open Access

    Resource use and costs of transitioning from paediatric to adult care for patients with chronic endocrine disease

    by Daniela Choukair, Janna Mittnacht, Dorothea Treiber, Georg F. Hoffmann, Corinna Grasemann, Angela Huebner, Reinhard Berner, Peter Burgard, Julia Szendroedi, Markus Bettendorf

    Objective: Structured transition of adolescents and young adults with a chronic endocrine disease from paediatric to adult care is important. Until now, no data on time and resources required for the necessary components of the transition process and the associated costs are available.Design, Patients and Measurements: In a prospective cohort study of 147 patients with chronic endocrinopathies, for the key elements of a structured transition pathway including (i) assessment of patients' disease‐related knowledge and needs, (ii) required education and counselling sessions, (iii) compiling an epicrisis and a transfer appointment of the patient together with the current paediatric and the future adult endocrinologist resource consumption and costs were determined.Results: One hundred and forty‐three of 147 enroled patients (97.3%) completed the transition pathway and were transferred to adult care. The mean time from the decision to start the transition process to the final transfer consultation was 399 ± 159 days. Transfer consultations were performed in 143 patients, including 128 patients jointly with the future adult endocrinologist. Most consultations were performed by a multidisciplinary team consisting of a paediatric and adult endocrinologist, psychologist, nurse, and a social worker acting also as a case manager with a median of three team members and lasted 87.6 ± 23.7 min. The mean cumulative costs per patient of all key elements were 519 ± 206 Euros. In addition, costs for case management through the transition process were 104.8 ± 28.0 Euros.Conclusions: Using chronic endocrine diseases as an example, it shows how to calculate the time and cost of a structured transition pathway from paediatric to adult care, which can serve as a starting point for sustainable funding for other chronic rare diseases.


  • Open Access

    CYP21A2 Gene Expression in a Humanized 21-Hydroxylase Mouse Model Does Not Affect Adrenocortical Morphology and Function

    by Tina Schubert, Nicole Reisch, Ronald Naumann, Ilka Reichardt, Dana Landgraf, Friederike Quitter, Shamini Ramkumar Thirumalasetty, Anne-Kristin Heninger, Mihail Sarov, Mirko Peitzsch, et al.

    Steroid 21-hydroxylase is an enzyme of the steroid pathway that is involved in the biosynthesis of cortisol and aldosterone by hydroxylation of 17α-hydroxyprogesterone and progesterone at the C21 position. Mutations in CYP21A2, the gene encoding 21-hydroxylase, cause the most frequent form of the autosomal recessive disorder congenital adrenal hyperplasia (CAH). In this study, we generated a humanized 21-hydroxylase mouse model as the first step to the generation of mutant mice with different CAH-causing mutations. We replaced the mouse Cyp21a1 gene with the human CYP21A2 gene using homologous recombination in combination with CRISPR/Cas9 technique. The aim of this study was to characterize the new humanized mouse model. All results described are related to the homozygous animals in comparison with wild-type mice. We show analogous expression patterns of human 21-hydroxylase by the murine promoter and regulatory elements in comparison to murine 21-hydroxylase in wild-type animals. As expected, no Cyp21a1 transcript was detected in homozygous CYP21A2 adrenal glands. Alterations in adrenal gene expression were observed for Cyp11a1, Star, and Cyb11b1. These differences, however, were not pathological. Outward appearance, viability, growth, and fertility were not affected in the humanized CYP21A2 mice. Plasma steroid levels of corticosterone and aldosterone showed no pathological reduction. In addition, adrenal gland morphology and zonation were similar in both the humanized and the wild-type mice. In conclusion, humanized homozygous CYP21A2 mice developed normally and showed no differences in histological analyses, no reduction in adrenal and gonadal gene expression, or in plasma steroids in comparison with wild-type littermates.


  • Open Access

    Genetic Analysis of Pediatric Primary Adrenal Insufficiency of Unknown Etiology: 25 Years’ Experience in the UK

    by Federica Buonocore, Avinaash Maharaj, Younus Qamar, Katrin Koehler, Jenifer P Suntharalingham, Li F Chan, Bruno Ferraz-De-Souza, Claire R Hughes, Lin Lin, Rathi Prasad, et al.

    Context Although primary adrenal insufficiency (PAI) in children and young people is often due to congenital adrenal hyperplasia (CAH) or autoimmunity, other genetic causes occur. The relative prevalence of these conditions is poorly understood. Objective We investigated genetic causes of PAI in children and young people over a 25 year period. Design, Setting and Participants Unpublished and published data were reviewed for 155 young people in the United Kingdom who underwent genetic analysis for PAI of unknown etiology in three major research centers between 1993 and 2018. We pre-excluded those with CAH, autoimmune, or metabolic causes. We obtained additional data from NR0B1 (DAX-1) clinical testing centers. Intervention and Outcome Measurements Genetic analysis involved a candidate gene approach (1993 onward) or next generation sequencing (NGS; targeted panels, exomes) (2013-2018). Results A genetic diagnosis was reached in 103/155 (66.5%) individuals. In 5 children the adrenal insufficiency resolved and no genetic cause was found. Pathogenic variants occurred in 11 genes: MC2R (adrenocorticotropin receptor; 30/155, 19.4%), NR0B1 (DAX-1; 7.7%), CYP11A1 (7.7%), AAAS (7.1%), NNT (6.5%), MRAP (4.5%), TXNRD2 (4.5%), STAR (3.9%), SAMD9 (3.2%), CDKN1C (1.3%), and NR5A1/steroidogenic factor-1 (SF-1; 0.6%). Additionally, 51 boys had NR0B1 variants identified through clinical testing. Although age at presentation, treatment, ancestral background, and birthweight can provide diagnostic clues, genetic testing was often needed to define the cause. Conclusions PAI in children and young people often has a genetic basis. Establishing the specific etiology can influence management of this lifelong condition. NGS approaches improve the diagnostic yield when many potential candidate genes are involved.


  • Top Cited Papers

    Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management

    by Hedi L Claahsen - van der Grinten, Phyllis W Speiser, S Faisal Ahmed, Wiebke Arlt, Richard J Auchus, Henrik Falhammar, Christa E Flück, Leonardo Guasti, Angela Huebner, Barbara B M Kortmann, et al.

    Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders affecting cortisol biosynthesis. Reduced activity of an enzyme required for cortisol production leads to chronic overstimulation of the adrenal cortex and accumulation of precursors proximal to the blocked enzymatic step. The most common form of CAH is caused by steroid 21-hydroxylase deficiency due to mutations in CYP21A2. Since the last publication summarizing CAH in Endocrine Reviews in 2000, there have been numerous new developments. These include more detailed understanding of steroidogenic pathways, refinements in neonatal screening, improved diagnostic measurements utilizing chromatography and mass spectrometry coupled with steroid profiling, and improved genotyping methods. Clinical trials of alternative medications and modes of delivery have been recently completed or are under way. Genetic and cell-based treatments are being explored. A large body of data concerning long-term outcomes in patients affected by CAH, including psychosexual well-being, has been enhanced by the establishment of disease registries. This review provides the reader with current insights in CAH with special attention to these new developments. Graphical Abstract Open in new tab Download slide


  • Open Access

    Increased Expression of Transthyretin in Leptin‐Deficient ob/ob Mice is not Causative for Their Major Phenotypic Abnormalities

    by C. Rendenbach, S. Ganswindt, S. Seitz, F. Barvencik, A. K. Huebner, A. Baranowsky, T. Streichert, A. Niemeier, J. Heeren, M. Amling, et al.

    The hormone leptin is a critical regulator of adipogenesis and energy metabolism. Similarly, leptin‐deficient ob/ob mice display various metabolic abnormalities, including not only obesity and insulin resistance, but also hypogonadism and high bone mass. By genome‐wide expression analysis using hypothalamus RNA from wild‐type and ob/ob mice, we observed the increased expression of the gene for transthyretin (Ttr) in the latter, as confirmed by quantitative real‐time‐polymerase chain reaction. Because Ttr encodes a carrier protein for retinol transport, and because we further found increased retinol levels in the serum of ob/ob mice, we investigated whether the additional absence of Ttr would influence the ob/ob phenotype. It was found that Ttr‐deficient ob/ob mice were indistinguishable from ob/ob littermates in terms of body weight, as well as serum glucose, insulin and cholesterol levels. Although all of these parameters were identical to wild‐type controls in Ttr‐deficient mice, we found that the sole deletion of Ttr caused a significant increase of trabecular bone mass, bone marrow adiposity and mean adipocyte area in white adipose tissue. Interestingly, all these latter parameters were highest in Ttr‐deficient ob/ob mice, and only in these mice did we observe a full penetrance of liver steatosis at 24 weeks of age. Taken together, our data demonstrate that the increased expression of Ttr in ob/ob mice does not cause (but rather attenuates) their phenotypic abnormalities.


  • G.P.8 08 Identification of a desmin gene mutation in scapuloperoneal syndrome type Kaeser

    by M.C. Walter, P. Reilich, A. Huebner, D. Fischer, M. Vorgerd, C. Born, J.R. Frey, H.E. Kaeser, H. Lochmüller